Welcome to our dedicated page for Atlassian Plc SEC filings (Ticker: TEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Atlassian builds Jira, Confluence and Bitbucket—tools that trace every story, bug and commit behind modern software projects. When the company files with the SEC, those same details appear in dense 10-K, 10-Q and 8-K exhibits that can exceed 300 pages. Our page brings those disclosures to life.
Explore Atlassian insider trading Form 4 transactions minutes after executives hit “submit.” Stock Titan’s AI clusters each Atlassian Form 4 insider transactions real-time feed, flagging option exercises, planned sales and unexpected buys. For governance questions, the latest Atlassian proxy statement executive compensation shows how equity awards align with Jira Cloud growth—our summaries distill the math.
The financial backbone is just as clear. Each Atlassian quarterly earnings report 10-Q filing is paired with cash-flow charts, margin trends and context around cloud migration. Need the annual big picture? See the Atlassian annual report 10-K simplified, where AI surfaces segment revenue, R&D spend and geographic breakdowns in plain English. Material updates arrive through Atlassian 8-K material events explained so you never miss acquisition news or guidance changes.
- AI-powered summaries turn 200+ pages into five-minute reads—understanding Atlassian SEC documents with AI.
- Keyword search across every exhibit for rapid Atlassian earnings report filing analysis.
- Instant alerts for Atlassian executive stock transactions Form 4.
Whether you’re tracking free-to-paid conversion metrics, monitoring dilution from stock-based compensation or comparing data-center versus cloud revenue, our platform keeps every filing current and clear. Stop scrolling through EDGAR PDFs; the insights you need are already organized the moment they’re filed.
Vir Biotechnology, Inc. (VIR) – Form 144 filing overview
The filing discloses a proposed secondary sale of 66,000 common shares of Vir Biotechnology under Rule 144. The shares were originally acquired on 17 Jan 2017 as pre-IPO stock and are held in the name of an undisclosed insider (the form does not specify the individual or relationship to the issuer). Morgan Stanley Smith Barney LLC, Executive Financial Services, is listed as the broker for the transaction.
- Shares to be sold: 66,000
- Aggregate market value: US $332,640
- Planned sale date: 1 Jul 2025
- Total VIR shares outstanding: 138,238,003
- Percent of shares outstanding: ~0.05 % (66,000 ÷ 138,238,003)
- Exchange: NASDAQ
No sales by the filer have occurred within the prior three months, and the securities were not purchased with non-cash consideration according to the disclosure. The seller certifies awareness of no undisclosed material adverse information and acknowledges potential criminal liability for misstatements.
Given the modest size relative to VIR’s float and the absence of multiple tranches or recent insider selling, this notice is unlikely to have a material impact on the company’s capital structure or market dynamics. However, investors may monitor for additional filings that could signal a broader disposition program.
Atlassian Corporation (TEAM) – Form 4 Insider Transaction
Co-CEO, Director and 10% owner Michael Cannon-Brookes reported three open-market sales of the company’s Class A common stock on 30 June 2025. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on 20 February 2025.
- Total shares sold: 7,665 (4,653 + 2,748 + 264)
- Weighted-average prices: $203.38, $202.70 and $204.12, respectively
- Aggregate value (approx.): $1.56 million
- Post-sale holdings: the trust (CBC Co Pty Ltd as trustee for the Cannon-Brookes Head Trust) now holds 3,012 TEAM shares; direct ownership lines show no remaining shares for the disclosed accounts.
The filing indicates the sales span a narrow $202–$204 price range, suggesting routine portfolio rebalancing rather than a reaction to unforeseen events. No derivative security activity was reported.
While the absolute dollar amount is modest relative to Cannon-Brookes’ multi-billion-dollar stake, any insider sale by a founder-CEO can attract investor attention. The use of a 10b5-1 plan provides an affirmative defense against allegations of trading on non-public information.
Atlassian Corporation (TEAM) – Form 4 Insider Transaction
Co-CEO, Director and 10% owner Michael Cannon-Brookes reported three open-market sales of the company’s Class A common stock on 30 June 2025. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on 20 February 2025.
- Total shares sold: 7,665 (4,653 + 2,748 + 264)
- Weighted-average prices: $203.38, $202.70 and $204.12, respectively
- Aggregate value (approx.): $1.56 million
- Post-sale holdings: the trust (CBC Co Pty Ltd as trustee for the Cannon-Brookes Head Trust) now holds 3,012 TEAM shares; direct ownership lines show no remaining shares for the disclosed accounts.
The filing indicates the sales span a narrow $202–$204 price range, suggesting routine portfolio rebalancing rather than a reaction to unforeseen events. No derivative security activity was reported.
While the absolute dollar amount is modest relative to Cannon-Brookes’ multi-billion-dollar stake, any insider sale by a founder-CEO can attract investor attention. The use of a 10b5-1 plan provides an affirmative defense against allegations of trading on non-public information.
Magnite, Inc. (MGNI) filed a Form 144 indicating a planned sale of 9,289 common shares worth approximately $204,358 at prevailing market prices. The shares were originally acquired on 02/15/2024 as restricted stock directly from the issuer and will be executed through Morgan Stanley Smith Barney LLC on or about 06/30/2025. Total shares outstanding are reported at 141,110,559, so the proposed sale represents less than 0.01 % of the float.
The filing lists David Buonasera as the selling shareholder, who has already disposed of 12,395 shares over the past three months for gross proceeds of $194,776.59. While the dollar amounts are modest relative to Magnite’s market capitalization, consecutive insider sales can raise sentiment concerns for some investors. The form contains no operational or financial performance data and makes no assertions about Magnite’s fundamentals; it solely discloses the insider’s intent to sell under Rule 144.
Credit Acceptance Corp. (NASDAQ: CACC) has filed an 8-K announcing execution of the Fourteenth Amendment to its $― revolving secured line of credit with Comerica Bank and a syndicate of lenders. The sole material change is an extension of the revolving period by 12 months—from 22 Jun 2027 to 22 Jun 2028. All other economic covenants, collateral requirements and pricing terms remain unchanged. As of the amendment date (24 Jun 2025), the Company had no outstanding borrowings under the facility, leaving the entire committed capacity available as contingent liquidity. The amendment appears to be routine and does not create additional debt; rather, it preserves an existing liquidity back-stop for a longer horizon. A related press release (Ex. 99.1) and the amended agreement (Ex. 4.155) were filed concurrently.
The filing does not disclose the credit line’s current size, pricing grid, or covenant thresholds, and it contains no earnings guidance, financial results, or changes in strategy. Therefore, the immediate market impact is expected to be modest, though the extension modestly strengthens the Company’s liquidity profile and financial flexibility.
Atlassian (NASDAQ:TEAM) filed a Form 4 reporting that CEO, director and 10% owner Michael Cannon-Brookes sold 7,665 Class A shares on 26 Jun 2025 under a Rule 10b5-1 plan adopted 20 Feb 2025.
The five tranches were executed at weighted-average prices between $196.79 – $200.39, raising roughly $1.5 million in gross proceeds. Following the sale, Cannon-Brookes holds 15,330 Class A shares indirectly via CBC Co Pty Ltd as trustee for the Cannon-Brookes Head Trust.
- No derivative transactions, option exercises or new corporate events were disclosed.
- Cannon-Brookes remains a director, CEO and 10% owner.
The filing is limited to the insider transaction and does not include operational or financial updates.
Atlassian (NASDAQ:TEAM) filed a Form 4 disclosing that co-founder, director and 10% owner Scott Farquhar sold 7,665 Class A shares on 26 Jun 2025 pursuant to a Rule 10b5-1 plan. Sale prices ranged from $196.79–$200.39, with weighted-average figures reported for each tranche, generating proceeds of roughly $1.5 million. Following the transactions, Farquhar, through Farquhar Investment Partnership No. 2, indirectly holds 15,330 shares, down from 22,995. No derivative trades were reported.
Atlassian (NASDAQ:TEAM) filed a Form 4 revealing that Co-Founder, CEO and 10 % owner Michael Cannon-Brookes sold 7,665 Class A shares on 25 June 2025 under a pre-arranged Rule 10b5-1 trading plan. Weighted-average prices ranged from $197.39 to $204.17, generating approximately $1.53 million in gross proceeds.
After the sales, Cannon-Brookes’ indirect holdings—held via CBC Co Pty Ltd as trustee for the Cannon-Brookes Head Trust—stand at 22,995 shares; direct holdings were unchanged and no derivatives were exercised. The disclosure represents a roughly 25 % reduction in the shares reported for this trust account.
While plan-based, the transaction size exceeds the $1 million materiality threshold and may influence investor sentiment given the insider’s leadership role.
Atlassian (NASDAQ:TEAM) filed a Form 4 showing co-founder, director and 10 % owner Scott Farquhar executed seven open-market sales on 25 Jun 2025 under a Rule 10b5-1 plan.
- Shares sold: 7,665
- Price range: $197.94 – $203.71 (weighted-average prices)
- Estimated proceeds: ≈ $1.53 million
- Remaining indirect holdings: 22,995 Class A shares via Farquhar Investment Partnership No. 2
No derivative transactions or option exercises were reported, and Farquhar retains all board roles. The trade trims the partnership’s position by roughly 25 %. While executed under a preset plan, the dollar value and insider’s prominence make the sale noteworthy for investors tracking sentiment and potential supply of TEAM shares.
Atlassian (NASDAQ:TEAM) CEO, director and 10% owner Michael Cannon-Brookes disclosed six open-market sales of Class A shares on 06/24/2025 under a Rule 10b5-1 plan adopted 02/20/2025.
The insider sold 7,665 shares at weighted-average prices of $195.20–$200.70, generating roughly $1.5 million in proceeds. His indirect holdings via CBC Co Pty Ltd. fell from 37,425 to 30,660 shares, an ~18% reduction. No derivative transactions occurred.
The magnitude (>5% of holdings and >$1 million) makes the trade potentially material for investor sentiment, although execution through a pre-set 10b5-1 plan lessens timing concerns.
FAQ
What is the current stock price of Atlassian Plc (TEAM)?
What is the market cap of Atlassian Plc (TEAM)?
What core services does Atlassian offer?
How does Atlassian generate its revenue?
Which industries primarily use Atlassian's products?
What distinguishes Atlassian from other software companies?
Can you explain Atlassian's business model in more detail?
What are the main benefits of using Atlassian's software?
How does Atlassian ensure its tools remain relevant in a competitive market?
Is Atlassian's focus more on cloud-based solutions or perpetual licensing?
